论文部分内容阅读
目的观察中药联合聚乙二醇干扰素α-2a治疗慢性丙型肝炎的临床疗效。方法将48例慢性丙型肝炎患者随机分为治疗组26例和对照组22例。对照组采用综合保肝、支持、对症等治疗措施,并予聚乙二醇干扰素α-2a皮下注射及利巴韦林口服,治疗组在此基础上加服中药;两组均治疗48周,观察临床疗效及治疗后肝功能、丙型肝炎病毒RNA(HCV-RNA)变化情况。结果治疗组、对照组总有效率分别为88.5%和86.4%,组间疗效差异无统计学意义(P>0.05);两组治疗后肝功能均较治疗前明显改善(P<0.05),组间治疗后差异有统计学意义(P<0.05);两组治疗后HCV-RNA定量均较治疗前明显下降(P<0.05),组间治疗后差异无统计学意义(P>0.05);治疗组不良反应明显少于对照组(P<0.05)。结论中药联合聚乙二醇干扰素α-2a治疗慢性丙型肝炎的疗效较好,不良反应发生率低。
Objective To observe the clinical efficacy of traditional Chinese medicine combined with pegylated interferon α-2a in the treatment of chronic hepatitis C Methods 48 patients with chronic hepatitis C were randomly divided into treatment group (n = 26) and control group (n = 22). In the control group, comprehensive treatment of hepatotoxicity, supportiveness, symptomatic treatment and other treatment measures were given. Peginterferon alfa-2a subcutaneously and ribavirin were given orally. On the basis of this, the treatment group added traditional Chinese medicine. Both groups were treated for 48 weeks , Observe the clinical efficacy and treatment of liver function, hepatitis C virus RNA (HCV-RNA) changes. Results The total effective rates of the treatment group and the control group were 88.5% and 86.4% respectively, with no significant difference between the two groups (P> 0.05). The liver function of the two groups was significantly improved after treatment (P <0.05) (P <0.05). The quantification of HCV-RNA in both groups after treatment was significantly lower than that before treatment (P <0.05), and there was no significant difference between the two groups after treatment (P> 0.05) Group adverse reaction was significantly less than the control group (P <0.05). Conclusion Chinese medicine combined with pegylated interferon alpha-2a in the treatment of chronic hepatitis C has a good curative effect and a low incidence of adverse reactions.